PASG Passage BIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PASG

Price (delayed)

$6

Market cap

$19.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.85

Enterprise value

-$8.33M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 12
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10

Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with ...

Highlights
The debt has plunged by 77% YoY and by 76% from the previous quarter
The EPS has grown by 41% YoY and by 17% from the previous quarter
The equity has plunged by 75% YoY and by 37% from the previous quarter
The quick ratio has shrunk by 53% YoY and by 17% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.passagebio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PASG

PASG stock price

How has the Passage BIO stock price performed over time
Intraday
0.5%
1 week
5.08%
1 month
31.29%
1 year
-37.89%
YTD
-49.15%
QTD
-23.57%

Financial performance

How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$37.68M
Net income
-$37.68M
Gross margin
N/A
Net margin
N/A
The operating income is up by 41% year-on-year and by 17% since the previous quarter
The net income is up by 41% year-on-year and by 17% since the previous quarter

Price vs fundamentals

How does PASG's price correlate with its fundamentals

Growth

What is Passage BIO's growth rate over time

Valuation

What is Passage BIO stock price valuation
P/E
N/A
P/B
1.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 41% YoY and by 17% from the previous quarter
The stock's price to book (P/B) is 104% more than its 5-year quarterly average of 0.8 and 16% more than its last 4 quarters average of 1.4
The equity has plunged by 75% YoY and by 37% from the previous quarter

Efficiency

How efficient is Passage BIO business performance
The company's return on equity has shrunk by 61% YoY and by 12% QoQ
The ROIC has contracted by 44% from the previous quarter

Dividends

What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PASG.

Financial health

How did Passage BIO financials performed over time
Passage BIO's total assets is 48% more than its total liabilities
Passage BIO's total assets has plunged by 58% YoY and by 41% from the previous quarter
Passage BIO's current ratio has plunged by 54% YoY and by 16% from the previous quarter
The debt is 51% less than the equity
The debt has plunged by 77% YoY and by 76% from the previous quarter
The equity has plunged by 75% YoY and by 37% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.